Home
Parallel Trade 2021 (Virtual Conference)
22 March - 23 March 2021

Post event on demand access to recorded presentations will be available to all attendees 5 working days from the end date of the event.

Parallel Trade 2021 (Virtual Conference)

SAE Media Group’s 15th Annual Conference
Parallel Trade 
March 22-23, 2021 | Virtual Conference
-------------------------------------------------------------------------
SAE Media Group presents its 15th annual Parallel Trade virtual conference on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.

This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.


 

FEATURED SPEAKERS

Beatriz San Martin

Beatriz San Martin

Partner, Arnold & Porter
Christopher Stothers

Christopher Stothers

Partner, Freshfields Bruckhaus Deringer LLP
Eric Noehrenberg

Eric Noehrenberg

President , NIPC
Jackie Mulryne

Jackie Mulryne

Partner - Life Science Regulatory, Arnold & Porter
Jan Grumiller

Jan Grumiller

Research Scientist, Austrian Foundation for Development Research (ÖFSE)
Kasia Bojarojc

Kasia Bojarojc

Senior Associate, Freshfields Bruckhaus Deringer LLP
Martin Slegl

Martin Slegl

Regional Principal of East Europe, IQVIA
Peter Bogaert

Peter Bogaert

Managing Partner, Covington & Burling
Soeren Brenoee

Soeren Brenoee

Senior Economist, Copenhagen Economics
Tine Petric

Tine Petric

Head Channel Management RE, Novartis Pharma AG
Vimal Unewal

Vimal Unewal

Senior Manager In Market Supply Europe, Ferring Pharmaceuticals Ltd

Beatriz San Martin

Partner, Arnold & Porter
Beatriz San Martin

Beatriz San Martin focuses her practice on the life sciences sector and innovative technologies. She has significant experience handling cases before the UK Courts and the Court of Justice of the European Union, including high-profile European litigation. In addition to her patent and SPC experience, she also counsels on and litigates other IP rights including copyright, trademark, passing off, design rights, database rights and confidential information. Her cases have involved a wide range of technologies including pharmaceuticals, medical devices, agrochemicals, insulation products, software, medical imaging and mosquito nets.

Christopher Stothers

Partner, Freshfields Bruckhaus Deringer LLP
Christopher Stothers

Christopher is a recognized expert in parallel trade, with a particular focus on the pharmaceutical sector - his 2007 textbook, “Parallel Trade in Europe: Intellectual Property, Competition and Regulatory Law,” has been cited by the UK Supreme Court. Christopher is also an experienced litigator on cross-border patent disputes, other types of intellectual property, antitrust, pharmaceutical regulation, EU law and commercial disputes. He has taken cases before the First Tier Tribunal, the Upper Tribunal, the Patents County Court, the High Court, the Court of Appeal, the House of Lords, the Supreme Court, the European Patent Office, and the European Court of Justice.

Eric Noehrenberg

President , NIPC
Eric Noehrenberg

Farasat Bokhari

Senior Lecturer, Associate Professor, UEA, University of East Anglia
Farasat Bokhari

Farasat Bokhari is an Associate Professor in the School of Economics and Centre for Competition Policy at the University of East Anglia. He is a health economist with a background in applied microeconomics and industrial organization, with a specialization in health policy. He has conducted research related to impact of public health financing on health outcomes as well as of other regulations on healthcare utilization. Dr. Bokhari’s research extends to competition and antitrust in the healthcare sector. His recent work is on welfare effects of new entrants, particularly of generic and follow-on (`me-too') drugs in the pharmaceutical markets. He has been active in studying firm strategies relating to pricing, launch of authorized generics, conducting pay-for-delay deals, and product differentiation and mergers and their impact on industry performance and structure.

Jackie Mulryne

Partner - Life Science Regulatory, Arnold & Porter
Jackie Mulryne

Jackie Mulryne advises clients in the life sciences and MedTech sectors, and has a broad practice providing regulatory compliance and public policy advice. She advises on UK and EU law, and has experience with a range of regulatory issues that arise throughout the product lifecycle. She regularly develops strategies to help bring innovative products to market, and has assisted a number of client in developing and implementing cross-border regulatory and compliance programmes.
Jackie also advises on contentious disputes in the sector, and has extensive experience in public and administrative law challenges to the decisions of regulatory bodies.

Jan Grumiller

Research Scientist, Austrian Foundation for Development Research (ÖFSE)
Jan Grumiller

Jan Grumiller is an economist at the Austrian Foundation for Development Research (ÖFSE). His area of expertise includes global value chains, international trade and industrial policy. He recently conducted studies for the European Parliament and the Austrian Chamber of Labour on the resilience of medical and pharmaceutical supply chains and potentials for reshoring.

John Schmidt

Partner, Arnold and Porter
John Schmidt

John Schmidt leads the UK Competition team in London. He has over 25 years of experience dealing with competition authorities and courts in the UK and the EU and regularly advises on complex competition conduct issues, investigations, litigation, and merger cases. He is dual-qualified in the UK and Germany and has a particular focus on the life sciences.
Mr. Schmidt has extensive experience advising pharmaceutical and medical device companies on pricing matters, including a number of reverse payment patent settlement cases both at the EU and UK level. He secured a number of case closures without an infringement findings in a number of CMA’s pharma investigations and he has assisted a number of companies in unannounced investigations by competition authorities.
Mr. Schmidt has been consistently ranked as a leading lawyer by Chambers UK ("very knowledgeable, easy to work with and adept at explaining complicated issues."), Chambers Europe, and Chambers Global, as well as The Legal 500.

Kasia Bojarojc

Senior Associate, Freshfields Bruckhaus Deringer LLP
Kasia Bojarojc

Kasia is a senior associate in Freshfields’ London antitrust, competition and trade practice group. Kasia previously worked as an associate in the Brussels office for four years, having completed a stage at the European Commission’s DG Competition. Kasia has also completed an in-house secondment with a multinational financial services client.
Kasia’s practice covers EU and UK competition law, including merger control and foreign investment antitrust, cartels, abuse of dominance and state aid. Kasia acts across a broad range of sectors as well as running the firm’s antitrust associate-led sector group focused on energy, infrastructure and regulated industries.
 

Martin Slegl

Regional Principal of East Europe, IQVIA
Martin Slegl

Martin has over 9 years experience in the area of management consulting, he was leading South East Europe consulting with IQVIA (10 countries). His current role is General Manager for the Czech Republic and Slovakia. His specialty is cross border trade and he has worked for a large number of HQs across Europe in different therapy areas. He has proven project experience across a variety of industries through Europe as he worked with Roland Berger and A.T. Kearney. Martin holds CEMS Master's in International Management and Master’s in Business Economics degrees from ESADE and University of Economics in Prague.

Peter Bogaert

Managing Partner, Covington & Burling
Peter Bogaert

Peter Bogaert

Managing Partner, Covington & Burling
Peter Bogaert

Peter Bogaert is a managing partner of the Brussels office, and has a broad European life sciences practice. He has detailed regulatory expertise under EU and national laws, handles legislative and other policy assignments and provides strategic advice. He also represents life sciences companies before the European Courts in Luxembourg and in local litigation in Belgium. Mr. Bogaert's practice covers pharmaceuticals, biotechnology, medical devices, special foods and feed, cosmetics and other consumer products and he represents numerous innovative life sciences companies, including start-ups, as well as several industry associations.
Chambers Global notes that a client said “He is an extremely experienced professional with broad expertise and provides sensible and well-balanced solutions." He is consistently ranked by PLC as one of the leading life sciences lawyers globally and Legal 500 EMEA and Chambers Europe note Mr. Bogaert's prominent regulatory pharmaceutical and environmental practice. Legal 500 EMEA (2011) noted that he is "a superb lawyer who is very pleasant to work with." Mr. Bogaert regularly writes and speaks on life sciences issues. He is a founding member of the Brussels Pharma Law Group.

Robert Bayerl

Engagement Manager, IQVIA Commercial GmbH & Co. OHG
Robert Bayerl

Shabnam Hanassab

Engagement Manager, IQVIA
Shabnam Hanassab

IQVIA’s expert and thought leader in European Parallel Trade dynamics, supply chain and distribution with several years of experience working in this field. Shabnam has developed in-depth expertise in pharmaceutical market dynamics and the increasing complexities of the trading environment. Shabnam is highly experienced on IQVIA’s data types, coverage and various supply chain offerings available centrally as well as locally, working with network of people within and outside organization. She has led several European supply chain consulting projects in the past few years. Shabnam holds BSc, MSc and PhD from University of London in Pharmaceutical and Computational Chemistry.
 

Soeren Brenoee

Senior Economist, Copenhagen Economics
Soeren Brenoee

Søren is an economics advisor within the field of healthcare and life sciences. He is the author of The economic impact of parallel imports of pharmaceuticals, a Danish study from 2019. His expe-rience ranges from design of value-based healthcare and risk-sharing models, impact evaluation, value demonstration of products and activities as well as strategic advice in relation to regulation. Søren is part of Copenhagen Economics, which is one of the leading economics firms in Europe, operating from offices in Copenhagen, Stockholm, Helsinki, and Brussels.

Tine Petric

Head Channel Management RE, Novartis Pharma AG
Tine Petric


Tine Petric has an in-depth knowledge on pharmaceutical parallel-trade with more than 6 years of hands-on experience in big Pharma. As Head of Channel Management at Novartis since 2017, Tine developed and implemented different commercial supply strategies across diverse European markets which contributed to minimizing impact of parallel trade on distribution costs and accessibility of medicinal products for patients. Before joining Channel management team, Tine was Head of business planning and analysis for South East Europe at Novartis, where he gained valuable experience in managing complex and diverse landscape of countries. Prior to joining Novartis, he held CFO positions in international manufacturing and power-exchange businesses.
Tine hold bachelor degree in international economics from University of Ljubljana, Slovenia and currently resides in Zurich, Switzerland.
 

Vimal Unewal

Senior Manager In Market Supply Europe, Ferring Pharmaceuticals Ltd
Vimal Unewal

Vimal Unewal is currently the Head of In-Market Supply for Ferring Pharmaceuticals, looking after the Parallel Trade across Europe. Vimal has 25 years of experience in supply chain and commercial across EMEA, Asian, Latin and North American markets for branded and generics pharmaceuticals, FMCG, and automotive. Vimal holds a B.Sc. in Business Management from University of Lisbon and a frequent speaker at supply chain conferences. Vimal lives in Berkshire (UK) and he’s interested in music and table tennis.

sponsors

Conference agenda

clock

9:00

Opening Remarks

clock

9:10

Intellectual Property and Free Movement

• Exhaustion of rights
• Repackaging of pharmaceuticals: the BMS conditions
• Recent case law and case study
 

Christopher Stothers

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

Kasia Bojarojc

Kasia Bojarojc, Senior Associate, Freshfields Bruckhaus Deringer LLP

clock

9:50

Competition Law

• Anti-competitive agreements and dominant positions
• Quotas and direct-to-pharmacy models
• Recent case law and case study
 

Christopher Stothers

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

Kasia Bojarojc

Kasia Bojarojc, Senior Associate, Freshfields Bruckhaus Deringer LLP

clock

10:30

Morning Coffee

clock

11:00

Regulatory Law

• Marketing authorisations
• Parallel import licences
• Recent case law and case study
 

Christopher Stothers

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

Kasia Bojarojc

Kasia Bojarojc, Senior Associate, Freshfields Bruckhaus Deringer LLP

clock

11:40

Covid-19 and Brexit

• How did Covid-19 affect the rules?
• How has Brexit affected the rules?
• Case study
 

Christopher Stothers

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

Kasia Bojarojc

Kasia Bojarojc, Senior Associate, Freshfields Bruckhaus Deringer LLP

clock

12:20

Closing Remarks

clock

13:30

Opening Remarks

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

13:35

SESSION 1 : GETTING THE STRATEGY RIGHT

clock

13:40

Internal & external challenges faced by pharma companies

• Organisation, roles & support from key functions
• Performance Measurement
• Supporting services and key data
 

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

14:00

Quantifying the business financial impact

• Reconciling imports with exports & why exports don’t match imports
• Getting to a complete picture
 

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

14:20

Selecting right distribution model/considerations before launch

• Go to market including pricing strategy
• Distribution channels
• Other
 

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

14:55

SESSION 2 : MASTERING THE EXECUTION

clock

15:00

Implementing a quota system in a country

• Case Study on Implementation
• What to anticipate
 

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

15:20

Enhancing effectiveness with e-prescription data

• Two case Studies on using e-Prescription data to gain patient insights and enhance distribution effectiveness

 

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

15:40

Parallel import sampling to support decision-making

• Designing a sampling survey and expected outcomes

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

16:00

Q&A and Concluding Remarks

Filippo Benetti

Filippo Benetti, Data Analytics Manager , Alira Health

Nerea Blanque

Nerea Blanque, Vice President Market Access and Pricing, Alira Health

Mark Inigo-Jones

Mark Inigo-Jones, Pharmaceutical Distribution & Parallel Trade Management Expert, Alira Health

clock

9:00

Chair's Opening Remarks

Eric Noehrenberg

Eric Noehrenberg, President , NIPC

clock

9:10

Managing Parallel Trade: An innovator’s perspective

Eric Noehrenberg

Eric Noehrenberg, President , NIPC

• Parallel trade makes medicines more “affordable”, but for whom?
• Impact of parallel trade
• Management of challenges posed by parallel trade

clock

9:50

Understanding the exhaustion of IP rights

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

• The traditional doctrine of EEA exhaustion
• Rebranding: Joined Cases C-253/20 and C-254/20 Impexeco / PI Pharma
• Exhaustion in Brexit Britain, now and in the future
 

clock

10:30

Morning Break

clock

11:00

Panel: Understanding how COVID-19 will continue to affect Parallel Trade

• Exploring how we have dealt with a shortage and restriction of medical products
• Examining how the supply chain has dealt with this shortage of products
• What has the export ban and the blocked movement of products meant for parallel trade?
• How are manufacturers going to supply during this period?
• Future implications?
 

Vimal Unewal, Senior Manager In Market Supply Europe, Ferring Pharmaceuticals Ltd

Tine Petric, Head Channel Management RE, Novartis Pharma AG

Eric Noehrenberg

Eric Noehrenberg, President , NIPC

clock

11:40

Analysing competition policies and Parallel trade

Kasia Bojarojc, Senior Associate, Freshfields Bruckhaus Deringer LLP

• Clear overview of the legal framework, whether as an introduction or refresher
• Practical and applied sessions using case studies
• Interactive workshop led by well-established practitioners
• Key takeaways of the Covid-19 and Brexit impact on the field

 

clock

12:20

Networking Break

clock

13:20

Case study: Pharma patent settlement

• IP strategy when considering a multijurisdictional patent settlement
• EU competition law implications and limitations in patent settlements
• Is it a battle between IP law vs competition law or do they seek achieve the same aims?
• Export bans/exhaustion/other restrictions/supply chains/Brexit and COVID
 

Beatriz San Martin, Partner, Arnold & Porter

John Schmidt, Partner, Arnold and Porter

clock

14:00

Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market

Farasat Bokhari, Senior Lecturer, Associate Professor, UEA, University of East Anglia

• Do innovative firms increase product lines to deter entry, and if so, when is such a strategy successful?
• Using data from UK pharmaceuticals to examine how incumbents respond to change in the threat of entry
• Examining the originators’ product launch rate is higher when the risk of entry is moderate, but becomes lower when entry is very likely, and the effect is most pronounced in medium size markets
• Exploring that in medium size markets, originators can deny entry via proliferation if they fill the product space evenly across patients so that each variant has a significant market share of the originator’s drugs
• Understanding that this does not work in large markets, but here entry is deterred when originators engage in product hopping, i.e., shift most of the patients to newer variants of the drug that may still be protected by intellectual property
 

clock

14:40

Afternoon Break

clock

15:10

Status Quo on the German PI market – Effects of recent legislation changes (GSAV in 2019)

Robert Bayerl

Robert Bayerl, Engagement Manager, IQVIA Commercial GmbH & Co. OHG

• PI incentives in Europe's biggest market - short history overview and recent changes (GSAV)
• Effects on products recently excluded from legal incentives
• Future challenges for the German PI market
 

clock

15:50

Chair’s Closing Remarks and Close of Day One

Eric Noehrenberg

Eric Noehrenberg, President , NIPC

clock

9:00

Chair's Opening Remarks

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

clock

9:10

The advantages of parallel imports from the payer’s perspective

Soeren Brenoee, Senior Economist, Copenhagen Economics

• What are the savings from parallel imports?
• How to quantify those savings?
• What regulation encourages and discourages parallel trade?
 

clock

9:50

Pinpointing the key trends of Parallel Trade within Europe

Shabnam Hanassab, Engagement Manager, IQVIA

• Overview of Parallel Trade sales trends across the EU in 2020
• Analysing the effect of Brexit and COVID-19 and their impact on supply chain
• Exploring the key drivers of parallel trade across Europe
 

clock

10:30

Morning Break

clock

11:00

Exploring cases associated with the Falsified Medicines Directive

Peter Bogaert, Managing Partner, Covington & Burling

• Examples of discussions points under the FMD
• What are we seeing in practice?
• What can we learn from these examples?
• Other experiences
• What countries are doing?
 

clock

11:40

Panel: Export bans and Parallel Trade

• Exploring how export bans are limiting sourcing opportunities of traders to understand how trade is decreasing
• Will these export bans be kept up in the future?
• Identifying the impact of COVID-19 on export bans in order to understand its significant effect on parallel trade
• What will happen with export bans once the COVID problems are solved?
 

Vimal Unewal, Senior Manager In Market Supply Europe, Ferring Pharmaceuticals Ltd

Soeren Brenoee, Senior Economist, Copenhagen Economics

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

clock

12:20

Networking Break

clock

13:20

Regulatory issues relevant to parallel trade

Jackie Mulryne, Partner - Life Science Regulatory, Arnold & Porter

• Overview of regulatory considerations, authorisations and licences
• Discussion of recent case law and current areas of dispute: including C-602/19, kohlpharma (changes to parallel import licences) and Case C-387/18, Delfarma (parallel trade of generic products)
• Outstanding questions, including C-147/20, Novartis (the impact of the Falsified Medicines Directive)
• Guidance from the EMA, including considerations where product is subject to special conditions for distribution
 

clock

14:00

Security of supply for medical and pharmaceutical goods: lessons from the pandemic

Jan Grumiller, Research Scientist, Austrian Foundation for Development Research (ÖFSE)

• Security of supply for medical and pharmaceutical products
• Recent policy discussions on increasing the resilience of global supply chains
• Reshoring as a solution?
 

clock

14:40

Afternoon Break

• Parallel trade makes medicines more “affordable”, but for whom?
• Impact of parallel trade
• Management of challenges posed by parallel trade
 

clock

15:10

Insights into Eastern Europe (EE)

Martin Slegl, Regional Principal of East Europe, IQVIA

• Updates about distribution legal changes across EE
• Availability of specialty drugs in EE post-Brexit
• EE as import market(s)
 

clock

15:50

Chairman’s Closing Remarks and Close of Day Two

Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP


Partner
Arnold & Porter
Partner
Freshfields Bruckhaus Deringer LLP
President
NIPC
Senior Lecturer, Associate Professor
UEA, University of East Anglia
Partner - Life Science Regulatory
Arnold & Porter
Research Scientist
Austrian Foundation for Development Research (ÖFSE)
Partner
Arnold and Porter
Senior Associate
Freshfields Bruckhaus Deringer LLP
Regional Principal of East Europe
IQVIA
Managing Partner
Covington & Burling
Managing Partner
Covington & Burling
Engagement Manager
IQVIA Commercial GmbH & Co. OHG
Engagement Manager
IQVIA
Senior Economist
Copenhagen Economics
Head Channel Management RE
Novartis Pharma AG
Senior Manager In Market Supply Europe
Ferring Pharmaceuticals Ltd

Sponsors

Supporting Media Partners

Workshops

Speaker interview with David Guest, MHRA

Download

Preliminary Attendees List 2021

Download

Speaker Interview with Boryana Marinkova, BAMPTD

Download

Speaker Interview with Christopher Stothers, Partner, Bruckhaus Freshfields Deringer

Download

Press release: Post conference Masterclass in EU Distribution

Download

Speaker interview with Kasper Ernest

Download

Speaker interview with Vimal Unewal, Ferring Pharmaceuticals

Download

Chair Letter 2021

Download

Speaker Interview with Dr Eric Noehrenberg, President, NIPC

Download

Parallel Trade Speakers bios 2021

Download

Parallel Trade Short Programme 2021

Download

Parallel Trade Full Programme 2021

Download

Past Attendees List

Download

PAST PRESENTATION BY Peter Bogaert & Wesley Lepla, Covington

Download

PAST PRESENTATION BY Jeremy Blum, Bristows LLP

Download

PAST PRESENTATION BY Dermott Glynn, Europe Economics

Download

PAST PRESENTATION BY Beatriz San Martin, Arnold & Porter

Download

Sponsors


Alira Health

Sponsors
https://www.alirahealth.com/

Alira Health is an international consulting firm focused on the healthcare and life science sector. We support our client’s business with a comprehensive service portfolio including Product Development, Regulatory, Clinical, Market Access, Strategic Consulting and Transaction Advisory services.

In the areas of European Distribution optimization Alira Health brings together multiple expertise in the areas of Market Access, Pricing, Distribution, Competition Law and data management to develop integrated leading-edge solutions for our clients.

Alira Health supports its clients in strategy development and implementation by providing project management expertise, internal team training (on best practices) and development of digital platforms that link proprietary data together with multiple externally sourced data into solutions tailored to clients’ needs.


Media Partners


Pharma Journalist

Supporting Media Partners
http://www.pharmajournalist.com

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


pharmanews hq

Supporting Media Partners
http://http://pharmanewshq.com

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


Gate2Biotech

Supporting Media Partners
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


World Pharma Today

Supporting Media Partners
http://www.worldpharmatoday.com



Farmavita

Supporting Media Partners
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


Pharmaceutical Outsourcing

Supporting Media Partners
http://www.pharmoutsourcing.com

Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


Drug Discovery Today

Supporting Media Partners
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


Pharmalicensing

Supporting Media Partners
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Technology Networks

Supporting Media Partners
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


PharmaVOICE

Supporting Media Partners
http://www.pharmavoice.com

PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


Biocompare

Supporting Media Partners
http://www.biocompare.com

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


Mednous

Supporting Media Partners
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Pharmiweb

Supporting Media Partners
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Pharmaceutical Technology

Supporting Media Partners
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


American Pharmaceutical Review

Supporting Media Partners
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


Pharmacircle

Supporting Media Partners
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

Online Virtual Event

Online Virtual Event
United Kingdom

Online Virtual Event

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

Group Booking

Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.